No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
NZ’s Pharmac Expands Funding of and Awards “Principal Supply Status” to Celltrion’s Bevacizumab Biosimilar
On 12 February 2025, New Zealand’s Pharmac announced that, from 1 March 2025, it will extend funding of Celltrion’s Vegzelma®, biosimilar to Roche/Genentech’s Avastin® (bevacizumab), for